Gly-Pro-D-Arg

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Gly-Pro-D-Arg
• 英文别名: (R)-2-((S)-1-(2-Aminoacetyl)pyrrolidine-2-carboxamido)-5-guanidinopentanoic acid；(2R)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
• 化学式: C₁₃H₂₄N₆O₄
• 分子量: 328.371
• InChiKey: JYPCXBJRLBHWME-BDAKNGLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.8
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  177
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-苯基偶氮苄氧羰基-L-PRO-LEU-GLY-PRO-D-ARG衍生物 在 盐酸 、 Streptomyces parvulus subsp. citrinus IFO 14435 collagenase 、 水 、 三羟甲基氨基甲烷 作用下， 生成 1-[({4-[(E)-苯基偶氮]苄基}氧基)羰基]脯氨酰亮氨酸 、 Gly-Pro-D-Arg
  参考文献：
  名称：

  Purification and Characterization of a Major Collagenase fromStreptomyces parvulus

  摘要：

  通过在 Q-Sepharose、Sephacryl S-200 和丁基-Toyopearl 上进行层析，从 Parvulus 链霉菌的粗酶样品中纯化出一种主要的胶原酶，纯化倍数约为 96 倍。纯化后的酶在 SDS-PAGE 上的相对分子质量约为 52,000，最适 pH 值约为 9.0，并受到金属螯合剂的强烈抑制。它还能特异性地裂解 4-苯基偶氮苄氧羰基-Pro-Leu-Gly-Pro-d-Arg 的 Leu-Gly 键，在 37 ℃、pH 值为 9.0 时的 K m 值为 0.60 mm。根据 N 端区域和内部胰蛋白酶肽的氨基酸序列，克隆了相应的基因。克隆基因的 DNA 序列表明，该酶是以 864 个残基的前体蛋白形式产生的，其中有 408 个残基的前导序列，随后是 456 个残基的成熟酶分子。该酶与 S. coelicolor 的胶原酶同源性最高，同源性为 73%，被认为是弧菌胶原酶亚家族的成员。

  DOI：

  10.1271/bbb.80357

文献信息

• Process for the production and purification of the collagenase enzyme from vibrio alginolyticus
  申请人：FIDIA FARMACEUTICI S.P.A.

  公开号：US10774319B2

  公开（公告）日：2020-09-15

  The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 11038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage. A further subject of the present invention is pharmaceutical compositions containing collagenase obtained according to the production and purification process described, for the purpose of therapeutic treatment of disorders characterised by collagen accumulation or for the treatment of blemishes/imperfections that benefit from reducing local collagen accumulations.

  本发明要求一种生产和纯化微生物胶原酶（微生物胶原酶 EC 3.4.24.3）的新工艺，该工艺由非致病性需氧细菌藻溶弧菌（Vibrio alginolyticus chemovar. iophagus）（NCIMB 编号：11038，同义词 LMG 3418，以下称藻溶弧菌）产生，所述工艺以稳定、可重复、廉价的发酵过程提供高水平的胶原酶生产。根据本发明所述工艺从藻类溶解弧菌中生产的胶原酶还具有优于其他微生物胶原酶的特异活性，在水溶液中稳定，可冷冻而无明显损伤。本发明的另一个主题是含有根据所述生产和纯化工艺获得的胶原蛋白酶的药物组合物，用于治疗以胶原蛋白蓄积为特征的疾病，或用于治疗因减少局部胶原蛋白蓄积而获益的色斑/瑕疵。
• NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS
  申请人：Fidia Farmaceutici S.p.A.

  公开号：EP2839000A1

  公开（公告）日：2015-02-25
• PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS
  申请人：FIDIA FARMACEUTICI S.P.A.

  公开号：US20200354707A1

  公开（公告）日：2020-11-12

  The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 11038, synonym LMG 3418, hereinafter called Vibrio alginolyticus ), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage. A further subject of the present invention is pharmaceutical compositions containing collagenase obtained according to the production and purification process described, for the purpose of therapeutic treatment of disorders characterised by collagen accumulation or for the treatment of blemishes/imperfections that benefit from reducing local collagen accumulations.
• US9738883B2
  申请人：——

  公开号：US9738883B2

  公开（公告）日：2017-08-22
• [EN] NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF THE COLLAGENASE ENZYME FROM VIBRIO ALGINOLYTICUS<br/>[FR] NOUVEAU PROCÉDÉ DE PRODUCTION ET DE PURIFICATION DE L'ENZYME COLLAGÉNASE ISSUE DE VIBRIO ALGINOLYTICUS
  申请人：FIDIA FARMACEUTICI

  公开号：WO2013156525A1

  公开（公告）日：2013-10-24

  The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage. A further subject of the present invention is pharmaceutical compositions containing collagenase obtained according to the production and purification process described, for the purpose of therapeutic treatment of disorders characterised by collagen accumulation or for the treatment of blemishes/imperfections that benefit from reducing local collagen accumulations.